Skip to main content
. 2020 Jul 29;10:12772. doi: 10.1038/s41598-020-69682-9

Figure 6.

Figure 6

Antitumor efficacy of EC2629 +/− anti-CTLA-4 on FR expressing intraperitoneal ID8-Cl15 tumors in C57BL/6 mice. ID8-Cl15 tumor cells (1 × 106) were inoculated intraperitoneally into C57BL/6 mice and therapy administered on randomized animals. open circle, untreated controls; filled circle, anti-CTLA-4 antibody 0.25 mg/dose, BIW, 5 doses; filled square, EC2629, 0.1 µmol/kg, BIW × 6 doses; filled diamond, EC2629+ anti-CTLA-4 antibody. N = 5 mice/group.